Jump to main content
US EPA
United States Environmental Protection Agency
Search
Search
Main menu
Environmental Topics
Laws & Regulations
About EPA
Health & Environmental Research Online (HERO)
Contact Us
Print
Feedback
Export to File
Search:
This record has one attached file:
Add More Files
Attach File(s):
Display Name for File*:
Save
Citation
Tags
HERO ID
7014003
Reference Type
Journal Article
Title
Use of exhaled breath condensate (EBC) in the diagnosis of SARS-COV-2 (COVID-19)
Author(s)
Ryan, DJ; Toomey, S; Madden, SF; Casey, M; Breathnach, OS; Morris, PG; Grogan, L; Branagan, P; Costello, RW; De Barra, E; Hurley, K; Gunaratnam, C; Mcelvaney, NG; Obrien, ME; Sulaiman, I; Morgan, RK; Hennessy, BT; ,
Year
2020
Is Peer Reviewed?
1
Journal
Thorax
ISSN:
0040-6376
EISSN:
1468-3296
Volume
76
Issue
1
Page Numbers
86-88
Language
English
PMID
33097604
DOI
10.1136/thoraxjnl-2020-215705
Web of Science Id
WOS:000608393000015
Abstract
False negatives from nasopharyngeal swabs (NPS) using reverse transcriptase PCR (RT-PCR) in SARS-CoV-2 are high. Exhaled breath condensate (EBC) contains lower respiratory droplets that may improve detection. We performed EBC RT-PCR for SARS-CoV-2 genes (E, S, N, ORF1ab) on NPS-positive (n=16) and NPS-negative/clinically positive COVID-19 patients (n=15) using two commercial assays. EBC detected SARS-CoV-2 in 93.5% (29/31) using the four genes. Pre-SARS-CoV-2 era controls (n=14) were negative. EBC was positive in NPS negative/clinically positive patients in 66.6% (10/15) using the identical E and S (E/S) gene assay used for NPS, 73.3% (11/15) using the N/ORF1ab assay and 14/15 (93.3%) combined.
Keywords
exhaled airway markers; respiratory infection; viral infection
Home
Learn about HERO
Using HERO
Search HERO
Projects in HERO
Risk Assessment
Transparency & Integrity